Drug Name: Defencath

Active Ingredient: taurolidine, heparin

Indication: To reduce the incidence of catheter-related bloodstream infections in adults with kidney failure receiving chronic hemodialysis through a central venous catheter (Catheter Lock Solution).

Approval Date: 11/15/2023

Company: CorMedix Inc

More: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/214520s000lbl.pdf

Leave a Reply

Your email address will not be published. Required fields are marked *